Erin Hertlein

2.4k citations

48 papers · 1.7k indexed · 1 hit paper · h-index 20

Impact in

Genetics top 1%
- Chronic Lymphocytic Leukemia Research
Pathology and Forensic Medicine top 2%
- Lymphoma Diagnosis and Treatment

Papers in

Genetics 25
- Chronic Lymphocytic Leukemia Research 22
Hematology 11
- Acute Myeloid Leukemia Research 10

Co-authors: John C. Byrd Amy J. Johnson Xiaoli Zhang Kristie A. Blum Sarah E. M. Herman Joseph J. Buggy Asha Ramanunni Jeffrey J. Jones
Journals: Blood (20 papers)Blood Advances (3 papers)Oncotarget (3 papers)Molecular and Cellular Biology (2 papers)Clinical Cancer Research (2 papers)
Partner nations: United States Germany Italy

In The Last Decade

Erin Hertlein

44 papers receiving 1.6k citations

Hit Papers

align trajectories log scale

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765 2011 · 607 citations

Peers

Countries citing papers authored by Erin Hertlein

Since Specialization

Citations

This map shows the geographic impact of Erin Hertlein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erin Hertlein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erin Hertlein more than expected).

Fields of papers citing papers by Erin Hertlein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erin Hertlein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erin Hertlein. The network helps show where Erin Hertlein may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Erin Hertlein, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Erin Hertlein Line = papers co-authored together Erin Hertlein links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Inhibition of Enhancer of Zeste Homolog 2 Induces Blast Differentiation, Impairs Engraftment and Prolongs Survival in Murine Models of Acute Myeloid Leukemia Cancers ·J. Zech, Ola A. Elgamal, Mark Wunderlich, 홍성두, 刘铁男, 辰二郎大川, S. M. Kusek, Zhihuan Zhou, Jianmin Pan, سارا میرجعفرزاده, Megan Johnstone, Amina Abdul‐Aziz, Donald Roy Howard, N. Shesh, John C. Byrd, Erin Hertlein	2024	1
2	Development of ZE66-0205, a Novel MALT1 Degrader for Treatment of B-Cell Malignancies Blood ·Sara Elgamal, 辰二郎大川, Aldo Mirabal Esparza, ثناء علي القباني, Zhihuan Zhou, Megan Johnstone, Jianmin Pan, N. Shesh, Alexander Khvat, Рубен Карапетян, Györy An, Елена А. Буланова, 西嶋寛之, Nikolay Savchuk, Iain Dukes, Amy Burd, Erin Hertlein, John C. Byrd	2024	1
3	Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study Blood Advances ·Bhavana Bhatnagar, Jessica Kohlschmidt, Shelley Orwick, Daelynn R. Buelow, J. Zech, Christopher C. Oakes, Jonathan E. Kolitz, Geoffrey L. Uy, Wendy Stock, Bayard L. Powell, Deedra Nicolet, Erin Hertlein, Krzysztof Mrózek, James S. Blachly, Ann‐Kathrin Eisfeld, Sharyn D. Baker, John C. Byrd	2023	1
4	The Potent Dihydroorotate Dehydrogenase Inhibitor, Hosu-53, Exhibits Compelling Monotherapy Efficacy in Multiple Myeloma and Augments CD47 Targeted Therapy Blood ·S. Vikashini, Fhabiana Thieli dos Santos Machado, Sandip Vibhute, Tiffany Hughes, Susheela Tridandapani, Megan Johnstone, Thomas E. Goodwin, Manuel De la Llata, Chad Bennett, Don Benson, John C. Byrd, Ola A. Elgamal, Erin Hertlein	2023	0
5	TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion Cancers ·Eric D. Eisenmann, R. Hoogerwerf, J. Zech, Kevin M. Huang, Daelynn R. Buelow, Shelley Orwick, 仙一成田, Efira Aflah Effendi, 崇高橋, Alice S. Mims, Erin Hertlein, John C. Byrd, Sharyn D. Baker	2022	7
6	Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients Leukemia ·Cecelia Miller, Ying Huang, Amy S. Ruppert, 陈辉吴启焰, Samantha Jaglowski, Kami J. Maddocks, Kerry A. Rogers, Seema A. Bhat, Adam S. Kittai, Michael R. Grever, Rosa Lapalombella, Lynne V. Abruzzo, Nyla A. Heerema, John C. Byrd, Erin Hertlein, Jennifer A. Woyach	2021	0
7	TP-0903 is active in models of drug-resistant acute myeloid leukemia JCI Insight ·仙一成田, Daelynn R. Buelow, Shubhkarman Kaur, Mingshan Niu, Eric D. Eisenmann, Kevin M. Huang, K Mahn, Efira Aflah Effendi, Clifford J. Whatcott, Jianyou Tian, Shelley Orwick, Vaezi Afsane, G. G. Gervinus, Lindsey T. Brinton, Rosa Lapalombella, James S. Blachly, Erin Hertlein, John C. Byrd, Bhavana Bhatnagar, Sharyn D. Baker	2020	21
8	Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia Journal of Hematology & Oncology ·Ola A. Elgamal, 刘铁男, 仙一成田, Vaezi Afsane, Amy Lehman, Shelley Orwick, 暢夫津田, Virginia M. Goettl, Thea Lien Espeland, Michael Sarnowski, Shaneice Mitchell, Rosa Lapalombella, Sudharshan Eathiraj, Brian Schwartz, Kimberly Stegmaier, Sharyn D. Baker, Erin Hertlein, John C. Byrd	2020	14
9	Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells Cancer Immunology Research ·C E Lee, Yung Ji Lim, Nikhil Gupta, Jeffrey A. Jones, Xiaokui Mo, Erin Hertlein, Lianbo Yu, Natarajan Muthusamy, John C. Byrd	2016	13
10	BRAFV600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation Leukemia Research ·J. Briffaud, Gerard Lozanski, Amy Lehman, Ellen J. Sass, Erin Hertlein, Santosh B. Salunke, Ching‐Shih Chen, Michael R. Grever, John C. Byrd, David Lucas	2015	6
11	Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia Oncotarget ·Kati Kämpjärvi, Tiina M. Järvinen, Tuomas Heikkinen, Amy S. Ruppert, Leigha Senter, Priscilla Schulte, Olli Dufva, Mika Kontro, Laura Z. Rassenti, Erin Hertlein, Thomas J. Kipps, Kimmo Porkka, John C. Byrd, Albert de la Chapelle, Pia Vahteristo	2014	35
12	The Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Cytotoxicity and an Atypical NF-κB Response in Chronic Lymphocytic Leukemia Cells Clinical Cancer Research ·Sneha Gupta, Erin Hertlein, Yanhui Lu, Ellen J. Sass, Rosa Lapalombella, Timothy L. Chen, Melanie E. Davis, Jennifer A. Woyach, Amy Lehman, David Jarjoura, John C. Byrd, David Lucas	2013	31
13	Fcγ Receptor-induced Soluble Vascular Endothelial Growth Factor Receptor-1 (VEGFR-1) Production Inhibits Angiogenesis and Enhances Efficacy of Anti-tumor Antibodies Journal of Biological Chemistry ·T. Huse, Laura Andrea Espitia Espitia, SHAIANE CAETANO CHAGAS, Prexy Shah, Payal Mehta, Julie M. Roda, Xiaokui Mo, Carolyn Cheney, Erin Hertlein, Timothy D. Eubank, Clay B. Marsh, Natarajan Muthusamy, Jonathan P. Butchar, John C. Byrd, Susheela Tridandapani	2013	11
14	Characterization of a New Chronic Lymphocytic Leukemia Cell Line for Mechanistic In Vitro and In Vivo Studies Relevant to Disease PLoS ONE ·Erin Hertlein, Kyle A. Beckwith, Gerard Lozanski, Timothy L. Chen, William H. Towns, Amy J. Johnson, Amy Lehman, Amy S. Ruppert, Brad Bolon, Leslie A. Andritsos, Arletta Lozanski, Laura Z. Rassenti, Weiqiang Zhao, Tiina M. Järvinen, Leigha Senter, Carlo M. Croce, David E. Symer, Albert de la Chapelle, Nyla A. Heerema, John C. Byrd	2013	46
15	OSU-T315, An Integrin-Linked Kinase (ILK) Inhibitor, Induces Apoptosis By Targeting B Cell Receptor and CD49d Mediated AKT/ERK Activation In Chronic Lymphocytic Leukemia Cells Blood ·Ta-Ming Liu, Yonghua Ling, Mitch A. Phelps, Jennifer A. Woyach, Erin Hertlein, William H. Towns, 克美島田, Santosh B. Salunke, Ching‐Shih Chen, John C. Byrd, Amy J. Johnson	2013	2
16	Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74+ B-cell Malignancies Clinical Cancer Research ·Yicheng Mao, Georgia Triantafillou, Erin Hertlein, William H. Towns, Matthew Stefanovski, Xiaokui Mo, David Jarjoura, Mitch A. Phelps, Guido Marcucci, Ly James Lee, David M. Goldenberg, Robert J. Lee, John C. Byrd, Natarajan Muthusamy	2012	26
17	Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765 Blood ·Sarah E. M. Herman, Amber Gordon, Erin Hertlein, Asha Ramanunni, Xiaoli Zhang, Samantha Jaglowski, Joseph M. Flynn, Jeffrey J. Jones, Kristie A. Blum, Joseph J. Buggy, Ahmed Hamdy, Amy J. Johnson, John C. Byrd Hit paper breakdown →	2011	607
18	Signalling to drug resistance in CLL Best Practice & Research Clinical Haematology ·Erin Hertlein, John C. Byrd	2010	22
19	Epigenetic alterations in a murine model for chronic lymphocytic leukemia Cell Cycle ·Shih-Shih Chen, Mara H. Sherman, Erin Hertlein, Amy J. Johnson, Michael A. Teitell, John C. Byrd, Christoph Plass	2009	21
20	ASC Directs NF-κB Activation by Regulating Receptor Interacting Protein-2 (RIP2) Caspase-1 Interactions The Journal of Immunology ·Anasuya Sarkar, Michelle Duncan, Judy Hart, Erin Hertlein, Denis C. Guttridge, Mark D. Wewers	2006	109

About Erin Hertlein

Erin Hertlein is a scholar working on Genetics, Hematology, Immunology, Pathology and Forensic Medicine and Oncology, having authored 48 papers that have together received 1.7k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (22 papers), Acute Myeloid Leukemia Research (10 papers), Lymphoma Diagnosis and Treatment (7 papers), Galectins and Cancer Biology (7 papers), Ubiquitin and proteasome pathways (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Immunodeficiency and Autoimmune Disorders (4 papers) and RNA Interference and Gene Delivery (3 papers). The work is most often cited by research in Genetics (768 citations), Pathology and Forensic Medicine (517 citations), Immunology (551 citations), Hematology (271 citations) and Cancer Research (231 citations). Erin Hertlein has collaborated with scholars based in United States, Germany and Italy. Frequent co-authors include John C. Byrd, Amy J. Johnson, Xiaoli Zhang, Kristie A. Blum, Sarah E. M. Herman, Joseph J. Buggy, Asha Ramanunni, Jeffrey J. Jones, Ahmed Hamdy and Amber Gordon. Their work appears in journals such as Blood, Blood Advances, Oncotarget, Molecular and Cellular Biology and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact